{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:18:38Z","timestamp":1765610318125,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Council Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>To increase the safety of adenovirus vector (AdV)-based therapy without reducing its efficacy, a single-cycle adenovirus vector (SC-AdV) with a deletion in the protease gene (PS) was developed in order to be used as a substitute for the replication-competent adenovirus (RC-AdV). Since no infectious viral particles are assembled, there is no risk of viral shedding. The complementary cell lines for this developed AdV proved to be suboptimal for the production of viral particles and require the presence of fetal bovine serum (FBS) to grow. In the current study, we produced both stable pools and clones using adherent and suspension cells expressing the PS gene. The best adherent cell pool can be used in the early stages for the generation of protease-deleted adenovirus, plaque purification, and titration. Using this, we produced over 3400 infectious viral particles per cell. Additionally, the best suspension subclone that was cultured in the absence of FBS yielded over 4000 infectious viral particles per cell. Harvesting time, culture media, and concentration of the inducer for the best suspension subclone were further characterized. With these two types of stable cells (pool and subclone), we successfully improved the titer of protease-deleted adenovirus in adherent and suspension cultures and eliminated the need for FBS during the scale-up production. Eight lots of SC-AdV were produced in the best suspension subclone at a scale of 2 to 8.2 L. The viral and infectious particle titers were influenced by the virus backbone and expressed transgene.<\/jats:p>","DOI":"10.3390\/cells12040619","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T03:37:24Z","timestamp":1676432244000},"page":"619","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Complementary Cell Lines for Protease Gene-Deleted Single-Cycle Adenovirus Vectors"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-5665","authenticated-orcid":false,"given":"Seyyed Mehdy","family":"Elahi","sequence":"first","affiliation":[{"name":"Department of Production Platforms & Analytics, National Research Council Canada, Building Montreal, Montreal, QC H4P 2R2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazila","family":"Nazemi-Moghaddam","sequence":"additional","affiliation":[{"name":"Department of Production Platforms & Analytics, National Research Council Canada, Building Montreal, Montreal, QC H4P 2R2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Guilbault","sequence":"additional","affiliation":[{"name":"Department of Production Platforms & Analytics, National Research Council Canada, Building Montreal, Montreal, QC H4P 2R2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Simoneau","sequence":"additional","affiliation":[{"name":"Department of Production Platforms & Analytics, National Research Council Canada, Building Montreal, Montreal, QC H4P 2R2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9nald","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Department of Production Platforms & Analytics, National Research Council Canada, Building Montreal, Montreal, QC H4P 2R2, Canada"},{"name":"Department of Bioengineering, McGill University, Montreal, QC H3A 0E9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5","volume":"36","author":"Graham","year":"1977","journal-title":"J. Gen. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2019.01182","article-title":"Oncolytic Adenovirus\u2014A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC","volume":"9","author":"Abudoureyimu","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1002\/jcp.27850","article-title":"Oncolytic Adenovirus: A Tool for Cancer Therapy in Combination with Other Therapeutic Approaches","volume":"234","author":"Goradel","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/OV.S196403","article-title":"Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma","volume":"8","author":"Kiyokawa","year":"2019","journal-title":"Oncolytic Virotherapy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.07.006","article-title":"Advances in Oncolytic Adenovirus Therapy for Pancreatic Cancer","volume":"434","author":"Nattress","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.virusres.2018.08.012","article-title":"Tropism and Transduction of Oncolytic Adenovirus 5 Vectors in Cancer Therapy: Focus on Fiber Chimerism and Mosaicism, Hexon and PIX","volume":"257","author":"Stepanenko","year":"2018","journal-title":"Virus Res."},{"key":"ref_7","first-page":"163","article-title":"Single-Cycle Adenovirus Vectors in the Current Vaccine Landscape","volume":"17","author":"Barry","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.virol.2014.05.030","article-title":"IIIa Deleted Adenovirus as a Single-Cycle Genome Replicating Vector","volume":"462\u2013463","author":"Crosby","year":"2014","journal-title":"Virology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Oualikene, W., Lamoureux, L., Weber, J.M., and Massie, B. (2000). Protease-Deleted Adenovirus Vectors and Complementing Cell Lines: Potential Applications of Single-Round Replication Mutants for Vaccination and Gene Therapy, Mary Ann Liebert, Inc.","DOI":"10.1089\/10430340050032438"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1158\/0008-5472.CAN-06-4317","article-title":"Improvement of Antitumor Activity by Gene Amplification with a Replicating but Nondisseminating Adenovirus","volume":"67","author":"Bourbeau","year":"2007","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/jvh.12856","article-title":"Development of a Recombinant Murine Tumour Model Using Hepatoma Cells Expressing Hepatitis C Virus Nonstructural Antigens","volume":"25","author":"Young","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1016\/j.vaccine.2019.08.079","article-title":"Evaluation of Recombinant Adenovirus Vectors and Adjuvanted Protein as a Heterologous Prime-Boost Strategy Using HER2 as a Model Antigen","volume":"37","author":"Haq","year":"2019","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.sbi.2016.06.005","article-title":"Recombinant Protein Production from Stable Mammalian Cell Lines and Pools","volume":"38","author":"Hacker","year":"2016","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/biot.201400821","article-title":"Optimized Sleeping Beauty Transposons Rapidly Generate Stable Transgenic Cell Lines","volume":"10","author":"Kowarz","year":"2015","journal-title":"Biotechnol. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/bit.22968","article-title":"Generation of Stable, High-Producing Cho Cell Lines by Lentiviral Vector-Mediated Gene Transfer in Serum-Free Suspension Culture","volume":"108","author":"Oberbek","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/156652309790031120","article-title":"State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations","volume":"9","author":"Pauwels","year":"2009","journal-title":"Curr. Gene Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/15665232113136660006","article-title":"Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy","volume":"13","author":"Rothe","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/gtc.12183","article-title":"Experimental Design for Stable Genetic Manipulation in Mammalian Cell Lines: Lentivirus and Alternatives","volume":"20","author":"Shearer","year":"2015","journal-title":"Genes Cells"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e3073","DOI":"10.21769\/BioProtoc.3073","article-title":"Generation of Stable Expression Mammalian Cell Lines Using Lentivirus","volume":"8","author":"Tandon","year":"2018","journal-title":"Bio-Protocol"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17361","DOI":"10.1038\/s41598-018-35407-2","article-title":"Enhanced Anti-Metastatic Bioactivity of an IGF-TRAP Re-Engineered to Improve Physicochemical Properties","volume":"8","author":"Vaniotis","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/mthe.2000.0238","article-title":"Generation of a Stable Cell Line Producing High-Titer Self-Inactivating Lentiviral Vectors","volume":"3","author":"Xu","year":"2001","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jbiotec.2010.03.020","article-title":"yuan Generation of Stable Cell Lines by Site-Specific Integration of Transgenes into Engineered Chinese Hamster Ovary Strains Using an FLP-FRT System","volume":"147","author":"Zhou","year":"2010","journal-title":"J. Biotechnol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mullick, A., Xu, Y., Warren, R., Koutroumanis, M., Guilbault, C., Broussau, S., Malenfant, F., Bourget, L., Lamoureux, L., and Lo, R. (2006). The Cumate Gene-Switch: A System for Regulated Expression in Mammalian Cells. BMC Biotechnol., 6.","DOI":"10.1186\/1472-6750-6-43"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1089\/104303403322542266","article-title":"A Coumermycin\/Novobiocin-Regulated Gene Expression System","volume":"14","author":"Zhao","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"ref_25","unstructured":"Castagner, F. (2002). \u00c9tablissement d\u2019une Lign\u00e9e Cellulaire Adh\u00e9rente Compl\u00e9mentant Les Vecteurs Ad\u00e9noviraux R\u00e9plicatifs Non-Diss\u00e9minatifs et D\u00e9veloppement de Vecteurs Ad\u00e9noviraux Pour La Vaccination G\u00e9n\u00e9tique Chez Les Porcs, Universit\u00e9 de Qu\u00e9bec."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jviromet.2014.08.013","article-title":"Establishment and Validation of New Complementing Cells for Production of E1-Deleted Adenovirus Vectors in Serum-Free Suspension Culture","volume":"208","author":"Gilbert","year":"2014","journal-title":"J. Virol. Methods"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.mt.6300383","article-title":"Inducible Packaging Cells for Large-Scale Production of Lentiviral Vectors in Serum-Free Suspension Culture","volume":"16","author":"Broussau","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1535-7163.MCT-14-0751","article-title":"The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis","volume":"14","author":"Wang","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/sj.gt.3301793","article-title":"Adenovirus-Based Libraries: Efficient Generation of Recombinant Adenoviruses by Positive Selection with the Adenovirus Protease","volume":"9","author":"Elahi","year":"2002","journal-title":"Gene Ther."},{"key":"ref_30","unstructured":"Dyson, M., and Durocher, Y. (2007). Expression Systems, Scion Publishing Ltd."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.2044-8295.1908.tb00176.x","article-title":"The Method of \u2018Right and Wrong Cases\u2019 (\u2018Constant Stimuli\u2019) without Gauss\u2019s Formulae","volume":"2","author":"Spearman","year":"1908","journal-title":"Br. J. Psychol. 1904-1920"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1021\/bp970110i","article-title":"Study of Adenovirus Production in Serum-Free 293SF Suspension Culture by GFP-Expression Monitoring","volume":"13","author":"Bourget","year":"1997","journal-title":"Biotechnol. Prog."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1128\/jvi.70.11.7498-7509.1996","article-title":"Evaluation of the Concentration and Bioactivity of Adenovirus Vectors for Gene Therapy","volume":"70","author":"Mittereder","year":"1996","journal-title":"J. Virol."},{"key":"ref_34","unstructured":"Elahi, S., Nazemi-Moghaddam, N., and Gilbert, R. (2023). Effects of E3 and E4 Deletion on the Replication and Transgene Expression of Single Cycle Adenovirus Vector. Montreal, QC, Canada. to be submitted."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"114267","DOI":"10.1016\/j.jviromet.2021.114267","article-title":"A Rapid Focus-Forming Assay for Quantification of Infectious Adenoviral Vectors","volume":"297","author":"Elahi","year":"2021","journal-title":"J. Virol. Methods"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/4\/619\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:35:28Z","timestamp":1760121328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/4\/619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cells12040619"],"URL":"https:\/\/doi.org\/10.3390\/cells12040619","relation":{},"ISSN":["2073-4409"],"issn-type":[{"type":"electronic","value":"2073-4409"}],"subject":[],"published":{"date-parts":[[2023,2,14]]}}}